Novel therapies for treating familial hypercholesterolemia

Related Experiment Video

Updated: May 5, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K

Salman J Bandeali1, Jad Daye, Salim S Virani

  • 1Section of Cardiology, Department of Medicine, Texas Heart Institute, St. Luke's Episcopal Hospital, 6720 Bertner, MC 1-133, Houston, TX, 77030, USA, salmanbandeali@hotmail.com.

Current Atherosclerosis Reports
|December 3, 2013
PubMed

Insights

Familial hypercholesterolemia causes early cardiovascular disease due to high LDL cholesterol. New therapies offer improved management beyond traditional treatments for this inherited condition.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Familial hypercholesterolemia (FH) is an inherited disorder leading to premature atherosclerosis and cardiovascular disease.
  • Individuals with FH exhibit extremely elevated low-density lipoprotein cholesterol (LDL-C) levels.
  • Conventional antihyperlipidemic medications often fail to achieve target LDL-C reductions in FH patients.

Purpose of the Study:

  • To provide a concise overview of familial hypercholesterolemia.
  • To discuss novel pharmacotherapies for managing FH.
  • To address the unmet need in FH treatment.

Main Methods:

  • Literature review of familial hypercholesterolemia.
  • Summary of current understanding of FH pathophysiology.
  • Discussion of recently approved and emerging pharmacotherapies targeting cholesterol pathways.

Main Results:

  • FH is characterized by genetic defects leading to severe hypercholesterolemia.
  • Novel therapies target various pathways, including PCSK9 inhibition and others.
  • These newer agents offer alternative or adjunctive treatment options.

Conclusions:

  • Familial hypercholesterolemia requires effective management strategies due to high cardiovascular risk.
  • Novel pharmacotherapies represent a significant advancement in treating FH.
  • Further research and clinical application of these therapies are crucial for improving patient outcomes.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613